Top Health Care companies in China by Price to Earnings Ratio (P/E)

This ranking features the top 417 Health Care companies in China ranked by Price to Earnings Ratio (P/E), averaging a Price to Earnings Ratio (P/E) of 32.26, for July 09, 2025.

#	Name	Market Capitalization Share Price Year-To-Date (YTD) return Revenue Revenue Year-on-Year (YoY) growth Operating Income EBIT EBITDA Free Cash Flow Dividend Yield Free Cash Flow Yield Total Assets Total Liabilities Cash and Short-Term Investments	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

…

Frequently Asked Questions

Which Health Care company in China has the highest Price to Earnings Ratio (P/E) ?

The Health Care company in China with the highest Price to Earnings Ratio (P/E) is Kangmei Pharmaceutical Co., Ltd. (Shanghai Stock Exchange: 600518.SS) at 3,356.42.

Which Health Care company in China has the lowest Price to Earnings Ratio (P/E) ?

The Health Care company in China with the lowest Price to Earnings Ratio (P/E) is Shanghai Bio-heart Biological Technology Co., Ltd. (HKSE: 2185.HK) at None.

What are the top 10 Health Care companies in China by Price to Earnings Ratio (P/E) ?

The top 10 Health Care companies in China by Price to Earnings Ratio (P/E) are Kangmei Pharmaceutical Co., Ltd., Sino Medical Sciences Technology Inc., Shanghai Yizhong Pharmaceutical Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Guangdong Lifestrong Pharmacy Co., Ltd., Strait Innovation Internet Co., Ltd., Tianjin Chase Sun Pharmaceutical Co.,Ltd, Beijing Bohui Innovation Biotechnology Group Co., Ltd., Chongqing Taiji Industry(Group) Co.,Ltd and Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd.

What are the bottom 10 Health Care companies in China by Price to Earnings Ratio (P/E) ?

The bottom 10 Health Care companies in China by Price to Earnings Ratio (P/E) are Shanghai Bio-heart Biological Technology Co., Ltd., I-Mab, China Pharma Holdings, Inc., HighTide Therapeutics Inc, Jiangsu Bioperfectus Technologies Co., Ltd., Innovent Biologics, Inc., China Reform Health Management and Services Group Co., Ltd., Nanjing Vazyme Biotech Co., Ltd., Chengdu Huasun Technology Group Inc., Ltd. and Dezhan Healthcare Company Limited.